Wells Fargo & Company Lucid Diagnostics Inc. Transaction History
Wells Fargo & Company
- $429 Billion
- Q1 2025
A detailed history of Wells Fargo & Company transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 2,150 shares of LUCD stock, worth $2,150. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,150
Previous 2,300
6.52%
Holding current value
$2,150
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LUCD
# of Institutions
65Shares Held
14.7MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.13MShares$4.13 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA2.73MShares$2.73 Million0.21% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.89MShares$1.89 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.58MShares$1.58 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL529KShares$529,4190.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $38.6M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...